COVID-19: How Effective Are the Repurposed Drugs and Novel Agents in Treating the Infection?

  • Chow Suet-May
  • Kuok Sin-Yee
  • Lee Jia-Qing
  • Goh Pey-Wen1 A/P Ranjit Singh
  • Timothy Tan Zhi-Zheng
  • Jhi-Biau Foo
  • Sharina Hamzah
  • Renukha Sellappans
  • Yow Hui-Yin


Coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has impacted the lives and  wellbeing of many people. This globally widespread disease poses a significant public health concern that urges to discover an effective treatment. This  review paper discusses the effectiveness of repurposed drugs used to treat COVID-19 and potential novel therapies for COVID-19. Among the various  repurposed drugs, remdesivir is the only agent approved by the Food and Drug Administration (FDA) to treat COVID-19. On the other hand, several drugs  have been listed in the Emergency Use Authorization (EUA) by the FDA to treat COVID-19, including casirivimab and imdevimab, baricitinib (in  combination with remdesivir), bamlanivimab, tocilizumab, and IL-6 inhibitors. In addition, in vitro and clinical studies have suggested cepharanthine,  sotrovimab, and XAV-19 as potential treatments to manage COVID-19. Due to inadequate understanding of COVID-19 and the rapid mutation of SARS-  CoV-2, COVID-19 remains a threat to global public health, with vaccination considered the most effective method to decrease COVID-19 transmission  currently. Nevertheless, with the intense efforts of clinical researchers globally, more promising treatments for COVID-19 will be established in the future. 


Journal Identifiers

eISSN: 1858-5051